prednisone has been researched along with lopinavir in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS | 1 |
| Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N | 1 |
| de Victoria Fernández, B; González Sánchez, IC; Redondo-Sendino, Á | 1 |
| Ambrosioni, J; Arranz, N; Bodro, M; Brunet, M; Castel, MÁ; Cofan, F; Crespo, G; Diekmann, F; Farrero, M; Forner, A; Gonzalez-García, R; LLigoña, A; Marcos, MÁ; Miró, JM; Moreno, A; Rodríguez-García, M; Roma, JR; Ruiz, P; Soy, D; Tuset, M | 1 |
1 review(s) available for prednisone and lopinavir
| Article | Year |
|---|---|
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Lung; Lupus Erythematosus, Systemic; Moxifloxacin; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Prednisone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
5 other study(ies) available for prednisone and lopinavir
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomycin; Dacarbazine; Doxorubicin; Female; Hematologic Diseases; HIV Infections; HIV Protease Inhibitors; Hodgkin Disease; Humans; Incidence; Kaplan-Meier Estimate; Lopinavir; Lung Diseases; Male; Mechlorethamine; Middle Aged; Nervous System Diseases; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Ritonavir; Vinblastine; Vincristine | 2012 |
[Skin manifestations associated with the new coronavirus SARS-CoV-2 disease].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Betacoronavirus; Betamethasone; Causality; Coronavirus Infections; COVID-19; Drug Eruptions; Drug Therapy, Combination; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prednisone; Ritonavir; SARS-CoV-2; Skin Diseases, Viral | 2020 |
Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
Topics: COVID-19; COVID-19 Drug Treatment; Drug Interactions; Humans; Lopinavir; Organ Transplantation; Prednisone; Protease Inhibitors; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients | 2023 |